Canada markets closed

I-Mab (0VY.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.3300-0.0400 (-2.92%)
At close: 08:03AM CEST
Full screen
Previous Close1.3700
Open1.3300
Bid1.3000 x N/A
Ask1.3200 x N/A
Day's Range1.3300 - 1.3300
52 Week Range1.0900 - 2.6800
Volume6,800
Avg. Volume134
Market Cap107.574M
Beta (5Y Monthly)1.08
PE Ratio (TTM)N/A
EPS (TTM)-2.2300
Earnings DateAug 15, 2024 - Aug 19, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.37
  • PR Newswire

    I-Mab Announces Leadership Transitions

    I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as the Chairman of the Board of Directors. He succeeds Dr. Pamela M. Klein, who steps down from I-Mab's Board of Directors and the Interim Chairperson position. Mr. Wei Fu has served as a member of the I-Mab Board of Directors since June 2018 and is the Chief Executive Officer of CBC Group, a healthcare asset management firm an

  • Simply Wall St.

    While private equity firms own 21% of I-Mab (NASDAQ:IMAB), retail investors are its largest shareholders with 59% ownership

    Key Insights Significant control over I-Mab by retail investors implies that the general public has more power to...

  • PR Newswire

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.